For instance, Lee TF et al. find that upregulated YAP expression in EGFR-mutant lung cancer cells led to the development of resistance against Epithelial Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib, afatinib and osimertinib [84]. Here, EGFR is linked to lung carcinoma.